PT - JOURNAL ARTICLE AU - Jeon, Yeonsu AU - Jeon, Sungwon AU - Choi, Whan-Hyuk AU - An, Kyungwhan AU - Choi, HanSol AU - Kim, Byoung-Chul AU - Kim, Weon AU - Lee, Sang Yeob AU - Bae, Jang-Whan AU - Hwang, Jin-Yong AU - Kang, Min Gyu AU - Kim, Yeonkyung AU - Kang, Younghui AU - Kim, Yeo Jin AU - Kim, Byung Chul AU - Bhak, Jong AU - Shin, Eun-Seok TI - Genome-wide analyses of early-onset acute myocardial infarction identify 29 novel loci by whole genome sequencing AID - 10.1101/2022.05.22.22275428 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.22.22275428 4099 - http://medrxiv.org/content/early/2022/05/25/2022.05.22.22275428.short 4100 - http://medrxiv.org/content/early/2022/05/25/2022.05.22.22275428.full AB - Early-onset acute myocardial infarction (AMI) may have a higher genetic predisposition than late-onset AMI does. The present study aimed to identify and characterize germline variants that affect early-onset AMI using whole-genome sequencing (WGS). We performed a genome-wide association study based on WGS of 1,239 Koreans, including 596 early-onset AMI patients and 643 healthy individuals. Patients with AMI who underwent percutaneous coronary intervention (PCI) caused by atherothrombotic occlusive lesions were included in the study. A total of 29 novel loci were found to be associated with early-onset AMI. These loci are involved in thrombosis, fibrinolysis, inflammation, and lipid metabolism. One of the associated single nucleotide variants (SNVs), rs1614576, located upstream of PRKCB, is known to be associated with thrombus formation. Additionally, the results revealed a novel locus, rs78631167, located upstream of PLAUR which plays a critical role in regulating plasminogen activation and is related to fibrinolysis. The association between early-onset AMI and rs9357455, which is located upstream of PHACTR1 that regulates inflammation in AMI, was found. Moreover, we could identify a lipid metabolism related genetic risk locus, rs5072, in the APOA1-AS gene. This study provides new evidence supporting the genetic association between early-onset AMI and thrombosis and fibrinolysis, as well as inflammation and lipid metabolism, by analyzing the whole-genome of 596 patients with early-onset AMI who have been treated with PCI. Our findings highlight potential genetic markers for the prediction and management of AMI, as well as for understanding the etiology of AMI.Competing Interest StatementSJ, BK, YK, and YJK were employed by Clinomics Inc. BCK and JB are the CEOs of Clinomics Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.Funding StatementThis work was supported by the Promotion of Innovative Businesses for Regulation-Free Special Zones funded by the Ministry of SMEs and Startups (MSS, Korea) [grant number P0016195, P0016193 (1425156792, 1425157301) (2.220035.01, 2.220036.01)]. This work was also supported by the Establishment of Demonstration Infrastructure for Regulation-Free Special Zones fund (MSS, Korea) [grant number P0016191 (2.220037.01) (1425157253)] by the Ministry of SMEs and Startups.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Ulsan National Institute of Science and Technology (UNISTIRB-15-19-A) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull summary statistics relating to the GWAS analysis and other relevant data are available upon request to the authors.AMIacute myocardial infarctionPCIpercutaneous coronary interventionGWASgenome-wide association studyWGSwhole-genome sequencingSNVsingle nucleotide variantKGPKorean Genome ProjectSTEMIST-segment elevation myocardial infarctionNSTEMInon-ST-segment elevation myocardial infarctionQTLquantitative trait locieQTLexpression QTLsQTLsplicing QTLmQTLmethylation QTLPRKCBprotein kinase C betaPLAURplasminogen activator, urokinase receptorPAFAH1B2platelet-activating factor acetylhydrolase 1b catalytic subunit 2PHACTR1phosphatase and actin regulator 1APOA1-ASapolipoprotein A1 antisense RNAPPIprotein-protein interaction